MA26812A1 - Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases - Google Patents

Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases

Info

Publication number: MA26812A1
Authority: MA; Morocco
Prior art keywords: triones; metalloproteinases; pyrimidine; inhibitors; triones inhibitors
Prior art date: 1999-08-12

Application number

MA26512A

Other languages

English (en)

Inventor

Blagg Julian

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-12

Filing date

2002-02-07

Publication date

2004-12-20

2002-02-07 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2004-12-20 Publication of MA26812A1 publication Critical patent/MA26812A1/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

MA26512A 1999-08-12 2002-02-07 Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases MA26812A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US14854799P	1999-08-12	1999-08-12

Publications (1)

Publication Number	Publication Date
MA26812A1 true MA26812A1 (fr)	2004-12-20

Family

ID=22526231

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA26512A MA26812A1 (fr)	1999-08-12	2002-02-07	Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases

Country Status (41)

Country	Link
US (1)	US6579982B1 (fr)
EP (1)	EP1202974B1 (fr)
JP (1)	JP2003507371A (fr)
KR (2)	KR20020047119A (fr)
CN (1)	CN1156454C (fr)
AR (1)	AR025091A1 (fr)
AT (1)	ATE309224T1 (fr)
AU (1)	AU773751B2 (fr)
BG (1)	BG106406A (fr)
BR (1)	BR0013081A (fr)
CA (1)	CA2381551A1 (fr)
CO (1)	CO5180629A1 (fr)
CR (1)	CR6565A (fr)
CZ (1)	CZ2002355A3 (fr)
DE (1)	DE60023903D1 (fr)
EA (1)	EA004680B1 (fr)
EC (1)	ECSP003610A (fr)
EE (1)	EE200200069A (fr)
GE (1)	GEP20053424B (fr)
GT (1)	GT200000137A (fr)
HK (1)	HK1045995B (fr)
HN (1)	HN2000000137A (fr)
HR (1)	HRP20020129A2 (fr)
HU (1)	HUP0202501A3 (fr)
IL (1)	IL148035A0 (fr)
IS (1)	IS6248A (fr)
MA (1)	MA26812A1 (fr)
MX (1)	MXPA02001561A (fr)
NO (1)	NO20020662L (fr)
NZ (1)	NZ516562A (fr)
OA (1)	OA12000A (fr)
PA (1)	PA8498701A1 (fr)
PE (1)	PE20010491A1 (fr)
PL (1)	PL353871A1 (fr)
SK (1)	SK1652002A3 (fr)
TN (1)	TNSN00169A1 (fr)
TR (1)	TR200200381T2 (fr)
UY (1)	UY26285A1 (fr)
WO (1)	WO2001012611A1 (fr)
YU (1)	YU6602A (fr)
ZA (1)	ZA200201070B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6833373B1 (en)	1998-12-23	2004-12-21	G.D. Searle & Co.	Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
PL366201A1 (en) *	2000-10-26	2005-01-24	Pfizer Products Inc.	Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
US6841671B2 (en)	2000-10-26	2005-01-11	Pfizer Inc.	Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
SK4872003A3 (en) *	2000-10-26	2004-08-03	Pfizer Prod Inc	Metaloproteinase pyrimidine-2,4,6-trione inhibitors
DOP2002000333A (es)	2001-02-14	2002-09-30	Warner Lambert Co	Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
PA8539501A1 (es)	2001-02-14	2002-09-30	Warner Lambert Co	Compuestos triazolo como inhibidores de mmp
JP2004518726A (ja)	2001-02-14	2004-06-24	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	ベンゾチアジアジンマトリックスメタロプロテイナーゼ阻害剤
DOP2002000332A (es)	2001-02-14	2002-08-30	Warner Lambert Co	Inhibidores de piridina de metaloproteinasas de la matriz
WO2002064571A1 (fr)	2001-02-14	2002-08-22	Warner-Lambert Company Llc	Pyrimidine comme inhibiteurs de la métalloprotéinase de matrice
US6924276B2 (en)	2001-09-10	2005-08-02	Warner-Lambert Company	Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
JP2003081838A (ja) *	2001-09-11	2003-03-19	Rohto Pharmaceut Co Ltd	グルコサミン製剤
US6962922B2 (en)	2001-10-12	2005-11-08	Warner-Lambert Company Llc	Alkynylated quinazoline compounds
JP4164028B2 (ja)	2001-10-12	2008-10-08	ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー	アルキンマトリックスメタロプロテイナーゼ阻害剤
AU2002346729A1 (en)	2001-12-20	2003-07-09	Bristol-Myers Squibb Company	Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases
US6894057B2 (en)	2002-03-08	2005-05-17	Warner-Lambert Company	Oxo-azabicyclic compounds
US7101883B2 (en)	2002-03-18	2006-09-05	Bristol-Myers Squibb Company	Uracil derivatives as inhibitors of TNF-α converting enzyme (TACE) and matrix metalloproteinases
ATE308544T1 (de) *	2002-04-26	2005-11-15	Pfizer Prod Inc	N-substituiete heteroaryloxy-aryl-spiro- pyrimidine-2,4,6-trion metalloproteinase inhibitoren
JP2005529889A (ja) *	2002-04-26	2005-10-06	ファイザー・プロダクツ・インク	ピリミジン−２，４，６−トリオンメタロ−プロテイナーゼ阻害剤
JP2005527598A (ja) *	2002-04-26	2005-09-15	ファイザー・プロダクツ・インク	トリアリール−オキシ−アリール−スピロ−ピリミジン−２，４，６−トリオンメタロプロテイナーゼ阻害剤
NI200300045A (es)	2002-04-26	2005-07-08	Pfizer Prod Inc	Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
WO2004014378A1 (fr)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Derives de 3-isoquinolinone utilises comme inhibiteurs de metalloprotease de matrice
JP2006504665A (ja)	2002-08-13	2006-02-09	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	マトリックスメタロプロテイナーゼ阻害剤としてのアザイソキノリン誘導体
WO2004014880A1 (fr)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Derives de chromone inhibiteurs de metalloproteinase de matrice
WO2004014923A1 (fr)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Inhibiteurs de metalloprotease bicycliques condenses avec la pyrimidinone
WO2004014909A1 (fr)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Derives fusionnes de la tetrahydropyridine inhibiteurs de la metalloprotease matricielle
BR0313459A (pt)	2002-08-13	2005-06-21	Warner Lambert Co	Derivados monocìclicos como inibidores de metaloproteinases de matriz
ATE359791T1 (de)	2002-08-13	2007-05-15	Warner Lambert Co	Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer
WO2004014375A2 (fr)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Inhibiteurs de metalloprotease bicycliques condenses
PA8578101A1 (es)	2002-08-13	2004-05-07	Warner Lambert Co	Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2004014908A1 (fr)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Inhibiteurs de metalloproteinases heterobicycliques
WO2004084903A1 (fr) *	2003-03-27	2004-10-07	F. Hoffmann-La Roche Ag	Utilisation d'une trioxopyrimidine pour le traitement et la prevention de l'angiogenese pathologique oculaire
WO2004084902A1 (fr) *	2003-03-28	2004-10-07	F. Hoffmann-La Roche Ag	Utilisation d'une trioxopyrimidine dans le traitement de lesions chroniques
ES2537514T3 (es)	2003-04-04	2015-06-09	Incyte Corporation	Composiciones, métodos y kits relacionados con la escisión de HER-2
US20050107350A1 (en) *	2003-08-22	2005-05-19	Pharmacia Corporation	Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
WO2012014109A1 (fr)	2010-07-30	2012-02-02	Ranbaxy Laboratories Limited	Sulfamides hétérocycliques servant d'inhibiteurs de synthétase d'arn de transfert, destinés à être utilisés en tant qu'agents antibactériens
TW201512171A (zh)	2013-04-19	2015-04-01	Pfizer Ltd	化學化合物
US20150366275A1 (en) *	2014-06-19	2015-12-24	Gyula Cserfoi	Wearable Signaling Device
GB201705255D0 (en)	2017-03-31	2017-05-17	Univ I Tromsø - Norges Arktiske Univ	Bioactive cyclic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20000035917A (ko) *	1996-08-28	2000-06-26	데이비드 엠 모이어	1,4-헤테로고리성 메탈로프로테아제 저해제
ES2247707T3 (es) *	1997-06-21	2006-03-01	Roche Diagnostics Gmbh	Derivados del acido barbiturico con actividad antimetastasica y antitumoral.

2000
- 2000-07-20 PA PA20008498701A patent/PA8498701A1/es unknown
- 2000-07-20 HN HN2000000137A patent/HN2000000137A/es unknown
- 2000-08-03 TR TR2002/00381T patent/TR200200381T2/xx unknown
- 2000-08-03 HU HU0202501A patent/HUP0202501A3/hu unknown
- 2000-08-03 MX MXPA02001561A patent/MXPA02001561A/es active IP Right Grant
- 2000-08-03 NZ NZ516562A patent/NZ516562A/xx unknown
- 2000-08-03 SK SK165-2002A patent/SK1652002A3/sk unknown
- 2000-08-03 CN CNB008113920A patent/CN1156454C/zh not_active Expired - Fee Related
- 2000-08-03 KR KR1020027001880A patent/KR20020047119A/ko active IP Right Grant
- 2000-08-03 EE EEP200200069A patent/EE200200069A/xx unknown
- 2000-08-03 AU AU60105/00A patent/AU773751B2/en not_active Ceased
- 2000-08-03 WO PCT/IB2000/001090 patent/WO2001012611A1/fr active IP Right Grant
- 2000-08-03 JP JP2001517509A patent/JP2003507371A/ja active Pending
- 2000-08-03 KR KR10-2004-7011899A patent/KR20040073608A/ko not_active Application Discontinuation
- 2000-08-03 CZ CZ2002355A patent/CZ2002355A3/cs unknown
- 2000-08-03 EP EP00946235A patent/EP1202974B1/fr not_active Expired - Lifetime
- 2000-08-03 IL IL14803500A patent/IL148035A0/xx unknown
- 2000-08-03 YU YU6602A patent/YU6602A/sh unknown
- 2000-08-03 DE DE60023903T patent/DE60023903D1/de not_active Expired - Lifetime
- 2000-08-03 OA OA1200200030A patent/OA12000A/en unknown
- 2000-08-03 CA CA002381551A patent/CA2381551A1/fr not_active Abandoned
- 2000-08-03 PL PL00353871A patent/PL353871A1/xx not_active Application Discontinuation
- 2000-08-03 GE GE4688A patent/GEP20053424B/en unknown
- 2000-08-03 EA EA200200058A patent/EA004680B1/ru not_active IP Right Cessation
- 2000-08-03 AT AT00946235T patent/ATE309224T1/de not_active IP Right Cessation
- 2000-08-03 BR BR0013081-8A patent/BR0013081A/pt not_active IP Right Cessation
- 2000-08-04 CO CO00058849A patent/CO5180629A1/es not_active Application Discontinuation
- 2000-08-09 US US09/635,156 patent/US6579982B1/en not_active Expired - Fee Related
- 2000-08-09 EC EC2000003610A patent/ECSP003610A/es unknown
- 2000-08-09 UY UY26285A patent/UY26285A1/es not_active Application Discontinuation
- 2000-08-10 AR ARP000104130A patent/AR025091A1/es unknown
- 2000-08-10 GT GT200000137A patent/GT200000137A/es unknown
- 2000-08-10 PE PE2000000811A patent/PE20010491A1/es not_active Application Discontinuation
- 2000-08-11 TN TNTNSN00169A patent/TNSN00169A1/fr unknown
2002
- 2002-01-25 IS IS6248A patent/IS6248A/is unknown
- 2002-01-29 CR CR6565A patent/CR6565A/es not_active Application Discontinuation
- 2002-02-07 MA MA26512A patent/MA26812A1/fr unknown
- 2002-02-07 ZA ZA200201070A patent/ZA200201070B/en unknown
- 2002-02-11 NO NO20020662A patent/NO20020662L/no not_active Application Discontinuation
- 2002-02-12 HR HR20020129A patent/HRP20020129A2/xx not_active Application Discontinuation
- 2002-02-12 BG BG06406A patent/BG106406A/xx unknown
- 2002-10-17 HK HK02107534.6A patent/HK1045995B/zh not_active IP Right Cessation

Also Published As

Publication number	Publication date
SK1652002A3 (en)	2002-09-10
CZ2002355A3 (cs)	2002-07-17
NO20020662D0 (no)	2002-02-11
US6579982B1 (en)	2003-06-17
IL148035A0 (en)	2002-09-12
ATE309224T1 (de)	2005-11-15
HK1045995B (zh)	2004-12-31
YU6602A (sh)	2004-11-25
PE20010491A1 (es)	2001-04-25
BG106406A (en)	2002-09-30
BR0013081A (pt)	2002-04-23
EP1202974B1 (fr)	2005-11-09
DE60023903D1 (de)	2005-12-15
TR200200381T2 (tr)	2002-05-21
ZA200201070B (en)	2003-04-30
WO2001012611A1 (fr)	2001-02-22
AU773751B2 (en)	2004-06-03
EA200200058A1 (ru)	2002-06-27
CN1368963A (zh)	2002-09-11
CO5180629A1 (es)	2002-07-30
CN1156454C (zh)	2004-07-07
EP1202974A1 (fr)	2002-05-08
JP2003507371A (ja)	2003-02-25
HUP0202501A2 (hu)	2002-12-28
HK1045995A1 (en)	2002-12-20
GEP20053424B (en)	2005-01-25
OA12000A (en)	2006-04-18
EE200200069A (et)	2003-04-15
AR025091A1 (es)	2002-11-06
UY26285A1 (es)	2001-03-16
HN2000000137A (es)	2001-02-02
NO20020662L (no)	2002-04-09
ECSP003610A (es)	2002-03-25
NZ516562A (en)	2003-06-30
GT200000137A (es)	2002-02-01
EA004680B1 (ru)	2004-06-24
KR20020047119A (ko)	2002-06-21
IS6248A (is)	2002-01-25
CR6565A (es)	2004-02-23
HUP0202501A3 (en)	2003-02-28
TNSN00169A1 (fr)	2005-11-10
CA2381551A1 (fr)	2001-02-22
PL353871A1 (en)	2003-12-01
KR20040073608A (ko)	2004-08-19
AU6010500A (en)	2001-03-13
HRP20020129A2 (en)	2004-04-30
PA8498701A1 (es)	2002-08-26
MXPA02001561A (es)	2002-07-02

Publication	Publication Date	Title
MA26812A1 (fr)	2004-12-20	Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases
AR028253A1 (es)	2003-04-30	Inhibidores de la glucogeno fosforilasa
FR15C0086I2 (fr)	2016-06-03	Derives d'hydroxamate en tant qu'inhibiteurs de desacetylase
ATE237329T1 (de)	2003-05-15	Metalloprotease inhibitoren
NO20031852D0 (no)	2003-04-24	Pyrimidin-2,4,6-trion metalloproteinase inhibitorer
NO20031853D0 (no)	2003-04-24	Spiro-pyrimidin-2,4,6-trion metalloproteinase inhibitorer
PT1224195E (pt)	2005-07-29	C-aril-glicosidos inibidores de tgls2
MA26881A1 (fr)	2004-12-20	5-alkyl-pyrido [2,3-d]pyrimidines inhibitrices de tyrosine-kinases.
ATE524441T1 (de)	2011-09-15	Vla-4-inhibitoren
MA27126A1 (fr)	2005-01-03	3'PROMEDICAMENTS DE 2'-DESOXY- β-L-NUCLEOSIDES
BR0000327B1 (pt)	2008-11-18	cabeÇa de poÇo.
DE50007243D1 (de)	2004-09-09	Säschar
AR028596A1 (es)	2003-05-14	Nuevos derivados de fenilglicina
PT1194404E (pt)	2006-08-31	Inibidores de aspartil-protease
NO20014243D0 (no)	2001-08-31	Dihetero-substituerte metalloprotease inhibitorer
PT1171440E (pt)	2004-07-30	3-ciano-¬1,7\|,¬1,5\|, e ¬1,8\|-naftiridinas substituidas inibidoras de tirosina quinases
DE59806475D1 (de)	2003-01-09	Urokinase-inhibitoren
FR2816843B1 (fr)	2006-10-27	Inhibiteurs de l'enzyme 5 alpha-reductase
ATE252547T1 (de)	2003-11-15	Matrixmetalloproteinaseinhibitoren
ATE277912T1 (de)	2004-10-15	Pyrimidine-2,4,6-trione als matrixmetalloproteinase-hemmer
DE60024101D1 (de)	2005-12-22	Enzyminhibitoren
DE60009260D1 (de)	2004-04-29	Thiopyranderivate as mmp-inhibitoren
EE200100084A (xx)	2002-08-15	NOS inhibiitorite uued farmatseutilised kasutusv�imalused
EE200100381A (et)	2002-12-16	Morfolinobensamiidi uued soolad
NO20022924L (no)	2002-06-18	Farnesyltransferase-inhibitorer